The opportunity is also with the platform, the development of the second and third generation maturation inhibitor is currently not taken into account, and should take shape in 2009.
Fuestein does not seem to be aware that Fuzeon was an injection that needed to be mixed prior, nothing to do with the liquid or pill formulation for Bev. His criticism would be more appropriate if he compared Bev to maraviroc. His criticism used to be that the pill is not taking shape, it is not planned for the end of the year.. Though it is true that management should have planned better from the start.
As for the need for more NNRTIs, you can't combine two NNRTIs so you need a head to head trial.
Congrats on the $500,000 GTCB deal today. Talk about small, that was .. cute. I didnt think GTCB would do a very valuable deal, but never thought the price of a house sorta.
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
